CN112771177A - 分子基因标签及其使用方法 - Google Patents

分子基因标签及其使用方法 Download PDF

Info

Publication number
CN112771177A
CN112771177A CN201980048546.5A CN201980048546A CN112771177A CN 112771177 A CN112771177 A CN 112771177A CN 201980048546 A CN201980048546 A CN 201980048546A CN 112771177 A CN112771177 A CN 112771177A
Authority
CN
China
Prior art keywords
hla
expression level
biological sample
cancer
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980048546.5A
Other languages
English (en)
Chinese (zh)
Inventor
S·沃伦
P·达纳赫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NS Wind Down Co Inc
Original Assignee
Nanostring Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanostring Technologies Inc filed Critical Nanostring Technologies Inc
Publication of CN112771177A publication Critical patent/CN112771177A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201980048546.5A 2018-05-21 2019-05-20 分子基因标签及其使用方法 Pending CN112771177A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862674285P 2018-05-21 2018-05-21
US62/674285 2018-05-21
US201862747853P 2018-10-19 2018-10-19
US62/747853 2018-10-19
PCT/US2019/033052 WO2019226514A2 (en) 2018-05-21 2019-05-20 Molecular gene signatures and methods of using same

Publications (1)

Publication Number Publication Date
CN112771177A true CN112771177A (zh) 2021-05-07

Family

ID=67002367

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980048546.5A Pending CN112771177A (zh) 2018-05-21 2019-05-20 分子基因标签及其使用方法

Country Status (7)

Country Link
US (1) US20210363590A1 (https=)
EP (1) EP3797173A2 (https=)
JP (2) JP2021524744A (https=)
CN (1) CN112771177A (https=)
AU (1) AU2019275404A1 (https=)
CA (1) CA3100200A1 (https=)
WO (1) WO2019226514A2 (https=)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113913507A (zh) * 2021-10-29 2022-01-11 温州医科大学附属第一医院 Ccl3蛋白作为评估非酒精性脂肪性肝病炎症水平及疾病进展的生物标志物的应用
CN114231623A (zh) * 2021-10-14 2022-03-25 福建中医药大学 Palmdelphin在制备人结直肠癌检测及治疗产品中的应用
CN115896290A (zh) * 2022-11-29 2023-04-04 中国人民解放军海军军医大学 Trim21基因检测在肿瘤诊断、治疗选择和预后评估中的应用
WO2024234348A1 (en) * 2023-05-17 2024-11-21 Yanjun Wang Biomarker for immune checkpoint blockade therapy in nsclc
CN119685476A (zh) * 2024-05-29 2025-03-25 深圳湾实验室 一种与癌症预后相关的基因标志物及其应用
CN119799905A (zh) * 2025-03-14 2025-04-11 浙江省肿瘤医院 乳头状甲状腺癌早期预测标志物、用途及其筛选方法

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113631908A (zh) * 2018-12-21 2021-11-09 纳米线科技公司 用于病理试样的移动数字空间剖析的方法、装置、系统和设备
CN115398011A (zh) * 2020-01-31 2022-11-25 亚拉勒提治疗欧洲私人有限公司 用于预测癌症患者的伊沙匹隆反应性的方法
ES2849965B2 (es) * 2020-02-21 2023-11-17 Fundacion Para La Investig E Innovacion Biosanitaria De Asturias Finba Ispa Metodo para predecir o pronosticar la respuesta al tratamiento del cancer
WO2021228888A1 (en) * 2020-05-12 2021-11-18 Asylia Diagnostics Biomarkers for hyperprogressive disease and therapy response after immunotherapy
US20230250173A1 (en) * 2020-07-01 2023-08-10 Pfizer Inc. Biomarkers for pd-1 axis binding antagonist therapy
WO2022012420A1 (zh) * 2020-07-17 2022-01-20 信达生物制药(苏州)有限公司 一种核苷酸组合及其应用
US12263233B2 (en) * 2020-10-19 2025-04-01 Washington University Compositions and methods for modulating Myc target protein 1
TW202241469A (zh) * 2021-02-20 2022-11-01 美商凱特製藥公司 免疫療法
JP2024508856A (ja) * 2021-03-01 2024-02-28 ジェネンテック， インコーポレイテッド 卵巣がんの診断方法及び処置方法
WO2022211620A1 (en) * 2021-04-01 2022-10-06 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Cd4/il-2 biomarker.
US20250002918A1 (en) * 2021-10-22 2025-01-02 The Wistar Institute Of Anatomy And Biology Compositions and methods for treatment of mic60 depleted cancers and metastasis
WO2023092119A2 (en) * 2021-11-22 2023-05-25 Ludwig Institute For Cancer Research Ltd Methods for predicting responsiveness to a cancer therapy
US20230257825A1 (en) * 2022-02-04 2023-08-17 City Of Hope Breast cancer biomarkers and methods of use
WO2023155021A1 (en) * 2022-02-18 2023-08-24 London Health Sciences Centre Research Inc. Immune classification tool for determining survival outcomes in cancer
WO2024227553A1 (en) * 2023-05-01 2024-11-07 The Chancellor, Masters And Scholars Of The University Of Oxford Biomarkers for use in cancer treatment and predicting responsiveness to a cancer therapy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1852974A (zh) * 2003-06-09 2006-10-25 密歇根大学董事会 用于治疗和诊断癌症的组合物和方法
CN101258238A (zh) * 2005-09-08 2008-09-03 迈世耐特股份公司 抗原呈递细胞的活化处理方法

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
EP0491007B1 (en) 1989-09-08 1996-03-13 The Johns Hopkins University Structural alterations of the egf receptor gene in human gliomas
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
DE69428764T2 (de) 1993-12-24 2002-06-20 Merck Patent Gmbh Immunokonjugate
US5654307A (en) 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
US5910486A (en) 1994-09-06 1999-06-08 Uab Research Foundation Methods for modulating protein function in cells using, intracellular antibody homologues
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
DE69536015D1 (de) 1995-03-30 2009-12-10 Pfizer Prod Inc Chinazolinone Derivate
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508537D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
JPH11507535A (ja) 1995-06-07 1999-07-06 イムクローン システムズ インコーポレイテッド 腫瘍の成長を抑制する抗体および抗体フラグメント類
SI9620103A (sl) 1995-07-06 1998-10-31 Novartis Ag Pirolopirimidini in postopki za njihovo pripravo
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
EA001595B1 (ru) 1996-04-12 2001-06-25 Варнер-Ламберт Компани Необратимые ингибиторы тирозинкиназ
AR007857A1 (es) 1996-07-13 1999-11-24 Glaxo Group Ltd Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen.
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
WO1998050038A1 (en) 1997-05-06 1998-11-12 American Cyanamid Company Use of quinazoline compounds for the treatment of polycystic kidney disease
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
BR9814116A (pt) 1997-11-06 2000-10-03 American Cyanamid Co Uso de derivados de quinazolina como inibidores de cinase de tirosina para tratamento de pólipo colÈnico
EA003786B1 (ru) 1998-11-19 2003-10-30 Варнер Ламберт Компани N-[4-(3-хлор-4-фторфениламино)-7-(3-морфолин-4-илпропокси)хиназолин-6-ил]акриламид - необратимый ингибитор тирозинкиназ
US7473767B2 (en) 2001-07-03 2009-01-06 The Institute For Systems Biology Methods for detection and quantification of analytes in complex mixtures
AU2003221684A1 (en) 2002-04-08 2003-10-27 Smithkline Beecham Corporation Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor
WO2005071419A2 (en) * 2004-01-16 2005-08-04 Ipsogen Protein expression profiling and breast cancer prognosis
JP5700911B2 (ja) 2005-12-23 2015-04-15 ナノストリング テクノロジーズ，インコーポレーテッド 配向され、固定化された巨大分子を含む組成物とその製造法
WO2007076128A2 (en) 2005-12-23 2007-07-05 Nanostring Technologies, Inc. Nanoreporters and methods of manufacturing and use thereof
CA2653095C (en) 2006-05-22 2013-07-16 Nanostring Technologies, Inc. Systems and methods for analyzing nanoreporters
US20090076734A1 (en) * 2007-03-22 2009-03-19 Torres-Roca Javier F Gene Signature for the Prediction of Radiation Therapy Response
CA2687292C (en) 2007-04-10 2017-07-04 Nanostring Technologies, Inc. Methods and computer systems for identifying target-specific sequences for use in nanoreporters
US8519115B2 (en) 2008-08-14 2013-08-27 Nanostring Technologies, Inc. Stable nanoreporters
EP2808402A3 (en) * 2008-12-29 2015-03-25 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Methods of predicting responsiveness to interferon treatment
WO2011047087A2 (en) 2009-10-13 2011-04-21 Nanostring Technologies, Inc. Protein detection via nanoreporters
WO2012129488A2 (en) * 2011-03-23 2012-09-27 Virginia Commonwealth University Gene signatures associated with rejection or recurrence of cancer
GB201217892D0 (en) 2012-10-05 2012-11-21 Virttu Biolog Ltd Treatment of cancer
SG11201502778TA (en) * 2012-10-12 2015-05-28 Agency Science Tech & Res Method of prognosis and stratification of ovarian cancer
AU2014278152A1 (en) 2013-06-14 2015-12-24 Nanostring Technologies, Inc. Multiplexable tag-based reporter system
EP3194440A1 (en) * 2014-09-15 2017-07-26 F. Hoffmann-La Roche AG Methods of treating cancer using pd-1 axis binding antagonist and il-17 binding antagonists
WO2016049276A1 (en) * 2014-09-25 2016-03-31 Moffitt Genetics Corporation Prognostic tumor biomarkers
US11377693B2 (en) * 2014-12-09 2022-07-05 Merck Sharp & Dohme Llc System and methods for deriving gene signature biomarkers of response to PD-1 antagonists
JP2018503373A (ja) * 2014-12-30 2018-02-08 ジェネンテック， インコーポレイテッド がんの予後診断及び治療のための方法及び組成物
ES2835866T5 (es) * 2015-05-12 2024-12-02 Hoffmann La Roche Procedimientos terapéuticos y de diagnóstico para el cáncer
SG10202107053QA (en) 2015-07-17 2021-08-30 Nanostring Technologies Inc Simultaneous quantification of gene expression in a user-defined region of a cross-sectioned tissue
WO2017096458A1 (en) * 2015-12-07 2017-06-15 Ontario Institute For Cancer Research (Oicr) Immune gene signature predictive of anthracycline benefit
WO2017216559A1 (en) * 2016-06-14 2017-12-21 Almac Diagnostics Limited Predicting responsiveness to therapy in prostate cancer
AU2017343779A1 (en) * 2016-10-13 2019-04-04 Dana-Farber Cancer Institute, Inc. Compositions and methods for predicting response and resistance to CTLA4 blockade in melanoma using a gene expression signature
EP3622092A4 (en) * 2017-05-11 2021-06-23 The Broad Institute, Inc. METHODS AND COMPOSITIONS OF USE OF CD8 + TUMOR-INFILTRATING LYMPHOCYTE SUBTYPES AND GENE SIGNATURES THEREOF
WO2019200223A1 (en) * 2018-04-13 2019-10-17 X4 Pharmaceuticals, Inc. Cancer serum biomarkers and methods of use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1852974A (zh) * 2003-06-09 2006-10-25 密歇根大学董事会 用于治疗和诊断癌症的组合物和方法
CN101258238A (zh) * 2005-09-08 2008-09-03 迈世耐特股份公司 抗原呈递细胞的活化处理方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
侯艳艳;刘涛;李欣;刘民;汤华;: "MKI67-siRNA可抑制QGY-7703细胞的生长", 中国生物化学与分子生物学报, no. 05, 20 May 2011 (2011-05-20) *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114231623A (zh) * 2021-10-14 2022-03-25 福建中医药大学 Palmdelphin在制备人结直肠癌检测及治疗产品中的应用
CN114231623B (zh) * 2021-10-14 2023-09-08 福建中医药大学 Palmdelphin在制备人结直肠癌检测及治疗产品中的应用
CN113913507A (zh) * 2021-10-29 2022-01-11 温州医科大学附属第一医院 Ccl3蛋白作为评估非酒精性脂肪性肝病炎症水平及疾病进展的生物标志物的应用
CN115896290A (zh) * 2022-11-29 2023-04-04 中国人民解放军海军军医大学 Trim21基因检测在肿瘤诊断、治疗选择和预后评估中的应用
CN115896290B (zh) * 2022-11-29 2023-11-24 中国人民解放军海军军医大学 Trim21基因检测在肿瘤诊断、治疗选择和预后评估中的应用
WO2024234348A1 (en) * 2023-05-17 2024-11-21 Yanjun Wang Biomarker for immune checkpoint blockade therapy in nsclc
CN119685476A (zh) * 2024-05-29 2025-03-25 深圳湾实验室 一种与癌症预后相关的基因标志物及其应用
CN119799905A (zh) * 2025-03-14 2025-04-11 浙江省肿瘤医院 乳头状甲状腺癌早期预测标志物、用途及其筛选方法

Also Published As

Publication number Publication date
EP3797173A2 (en) 2021-03-31
AU2019275404A1 (en) 2020-12-03
CA3100200A1 (en) 2019-11-28
JP2021524744A (ja) 2021-09-16
WO2019226514A2 (en) 2019-11-28
JP2024053048A (ja) 2024-04-12
WO2019226514A3 (en) 2019-12-26
US20210363590A1 (en) 2021-11-25

Similar Documents

Publication Publication Date Title
US12385098B2 (en) Methods and compositions for prognosis and treatment of cancers
CN112771177A (zh) 分子基因标签及其使用方法
US20170253933A1 (en) Compositions and methods for treating and diagnosing chemotherapy-resistant cancers
JP2018505658A (ja) Ｐｄ−１アンタゴニストに対する応答の遺伝子シグネチャーバイオマーカーを得るための系および方法
JP7236164B2 (ja) 治療法に対する応答を予測する薬剤及び方法
BRPI0808418A2 (pt) Predição de resposta a um inibidor de her
US12183434B2 (en) Diagnostic and therapeutic methods for cancer
US20230391875A1 (en) Diagnostic and therapeutic methods for cancer
US20220380854A1 (en) ANGIOGENESIS AND mMDSC GENE EXPRESSION BASED BIOMARKER OF TUMOR RESPONSE TO PD-1 ANTAGONISTS
JP7520389B2 (ja) Ｔ細胞機能を評価して治療法に対する応答を予測するための方法および薬剤
WO2020223233A1 (en) Prognostic and therapeutic methods for colorectal cancer
HK1244302A1 (en) Methods and compositions for prognosis and treatment of cancers
HK1230250A1 (en) Diagnostic methods and compositions for treatment of glioblastoma

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210507

WD01 Invention patent application deemed withdrawn after publication